Skip to main content
. 2021 Jul 28;2021(7):CD015017. doi: 10.1002/14651858.CD015017.pub2

2.5. Analysis.

2.5

Comparison 2: Ivermectin compared to placebo or standard of care for people with mild COVID‐19 treated in the outpatient setting, Outcome 5: Duration to symptom resolution (secondary analysis)